{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:00:10Z","timestamp":1794373210400,"version":"4.9.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ygyno.2024.10.006","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T20:58:09Z","timestamp":1729630689000},"page":"172-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent\/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a\/1b EMBER study"],"prefix":"10.1016","volume":"191","author":[{"given":"Kan","family":"Yonemori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Gun","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek M.","family":"Meniawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Lombard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Okera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik V.","family":"Giridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Angel","family":"Garc\u00eda-S\u00e1enz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard Doger","family":"de Speville Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don S.","family":"Dizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garcia-Corbacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Van Nieuwenhuysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn T.","family":"Estrem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bacchion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roohi","family":"Ismail-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan","family":"Banda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.10.006_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0010","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/ijgc-2023-005031","article-title":"Combination of hormonal-based therapy in endometrial cancer: ready for prime time","volume":"33","author":"Santia","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.10.006_bb0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ygyno.2018.12.018","article-title":"Endocrine therapy in endometrial cancer: an old dog with new tricks","volume":"153","author":"Jerzak","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0025","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2001.19.2.364","article-title":"Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study","volume":"19","author":"Thigpen","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0030","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3389\/fonc.2019.00359","article-title":"Anti-estrogen treatment in endometrial Cancer: a systematic review","volume":"9","author":"van Weelden","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0035","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1517\/13543784.2016.1154532","article-title":"Fulvestrant for the treatment of endometrial cancer","volume":"25","author":"Battista","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ygyno.2024.10.006_bb0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jan.13818","article-title":"The fear of needles: a systematic review and meta-analysis","volume":"75","author":"McLenon","year":"2019","journal-title":"J. Adv. Nurs."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40487-017-0046-2","article-title":"A review of Fulvestrant in breast Cancer","volume":"5","author":"Nathan","year":"2017","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0050","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1136\/ijgc-2023-004739","article-title":"The promise of combining CDK4\/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma","volume":"33","author":"Ray-Coquard","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.10.006_bb0055","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"A phase II, two-stage study of Letrozole and Abemaciclib in estrogen receptor-positive recurrent endometrial Cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0060","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Colon-Otero","year":"2020","journal-title":"ESMO Open."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0065","doi-asserted-by":"crossref","first-page":"S1160","DOI":"10.1016\/j.annonc.2020.08.2258","article-title":"LBA28 a randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced\/recurrent endometrial cancer (EC): NSGO-PALEO \/ ENGOT-EN3 trial","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0070","first-page":"650","article-title":"The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Ma","year":"2004","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.10.006_bb0075","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1006\/gyno.2000.5865","article-title":"A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a gynecologic oncology group study","volume":"78","author":"Rose","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0080","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-19-3091","article-title":"Anastrozole has an association between degree of estrogen suppression and outcomes in early breast Cancer and is a ligand for estrogen receptor alpha","volume":"26","author":"Ingle","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0085","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-OT1-04-02","article-title":"Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: a prospective trial","volume":"83","author":"Haddad","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115422","article-title":"Selective estrogen receptor degraders (SERDs) for the treatment of breast cancer: an overview","volume":"256","author":"Bhatia","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2024.10.006_bb0095","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2021.39.15_suppl.1050","article-title":"A first-in-human phase 1a\/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): results from the EMBER study","volume":"39","author":"Jhaveri","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0100","first-page":"101218","article-title":"Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model","volume":"8","author":"VandeKopple","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0105","first-page":"23.02733","article-title":"Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with targeted therapy in ER-positive, HER2-negative advanced breast cancer: phase 1a\/1b EMBER study","author":"Jhaveri","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0110","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/10543406.2019.1636811","article-title":"The i3+3 design for phase I clinical trials","volume":"30","author":"Liu","year":"2020","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0115","series-title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update","first-page":"1346","volume":"38","author":"Allison","year":"2020"},{"key":"10.1016\/j.ygyno.2024.10.006_bb0120","author":"FDA"},{"key":"10.1016\/j.ygyno.2024.10.006_bb0125","author":"FDA"},{"key":"10.1016\/j.ygyno.2024.10.006_bb0130","author":"FDA"},{"key":"10.1016\/j.ygyno.2024.10.006_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101157","article-title":"Lenvatinib plus pembrolizumab a new effective combination of targeted agents","volume":"8","author":"Perez-Fidalgo","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0140","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1136\/ijgc-2023-004454","article-title":"Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: when is hormonal-based therapy the preferred option?","volume":"33","author":"Mahdi","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.10.006_bb0145","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0150","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial Cancer: diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"The Cancer genome atlas research network. Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2024.10.006_bb0160","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib as initial therapy for advanced breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2019.04.010","article-title":"Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies","volume":"154","author":"Gaillard","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0170","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1186\/s12885-023-11559-x","article-title":"Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma","volume":"23","author":"Drouyer","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2024.10.006_bb0175","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221113694","article-title":"Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role","volume":"14","author":"Lloyd","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0180","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ygyno.2013.02.039","article-title":"Phase II study of fulvestrant 250 mg\/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynakologische Onkologie","volume":"129","author":"Emons","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2019.05.007","article-title":"Phase 2 study of anastrozole in recurrent estrogen (ER)\/progesterone (PR) positive endometrial cancer: the PARAGON trial - ANZGOG 0903","volume":"154","author":"Mileshkin","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0190","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in combination with Fulvestrant in women with HR+\/HER2\u2212 advanced breast Cancer who had progressed while receiving endocrine therapy","volume":"35","author":"George","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.006_bb0195","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/onco.13531","article-title":"Management of Abemaciclib-Associated Adverse Events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast Cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2024.10.006_bb0200","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00428-020-03007-z","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"478","author":"Concin","year":"2021","journal-title":"Virchows Arch."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T01:52:31Z","timestamp":1733881951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824011569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":40,"alternative-id":["S0090825824011569"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.10.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent\/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a\/1b EMBER study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Eli Lilly and Company. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}